Data Provided by Refinitiv. Minimum 15 minutes delayed.

Investor Home

Investor Home

As a biopharmaceutical company focused on creating cutting-edge therapies and technologies for patients with diabetes and orphan lung diseases, MannKind is on a mission to help people take control of their health. Our approved product, Afrezza® (insulin human) Inhalation Powder, is an ultra rapid-acting inhaled insulin that was approved by the U.S. FDA in June 2014 and became available by prescription in U.S. pharmacies in February 2015. Afrezza utilizes our proprietary Technosphere® Technology, an innovative, dry-powder formulation technology that allows medication to be delivered through the lungs.
investor FAQs
Show All
When was MannKind Corporation founded?

February 1991.

What is your fiscal year?

December 31

On which exchange does MannKind trade and what is the symbol?

Nasdaq: MNKD

How do I contact your Investor Relations?

To contact MannKind’s Investor Relations, please fill out the online information request form or e-mail:

Where is MannKind located?
1 Casper Street
Danbury, CT 06810
30930 Russell Ranch Road, Suite 300
Westlake Village, CA 91362
Who is your transfer agent?


Mailing Address

P.O. Box 43006

Providence RI 02940-3006


Courier Delivery:

150 Royall St., Suite 101

Canton, MA 02021

Data Provided by Refinitiv. Minimum 15 minutes delayed.